A carregar...

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S(®) coated modified release formulations of mesalamine, such as Asacol(®), remain among the most popular choices. We here review the current...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Doherty, Glen A, Peppercorn, Mark A
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2009
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3108647/
https://ncbi.nlm.nih.gov/pubmed/21694838
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!